When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Hepatalin - Wikipedia

   en.wikipedia.org/wiki/Hepatalin

   In response to an intravenous injection of insulin after a meal, hepatalin action accounted for approximately 55% of the glucose uptake (in rats [11]) and 66% (in humans [12]). The partitioning of the nutrient energy storage process in a healthy body is dependent on the ratio of insulin and hepatalin action.

3. Diabetes medication - Wikipedia

   en.wikipedia.org/wiki/Diabetes_medication

   Drugs used in diabetes treat types of diabetes mellitus by decreasing glucose levels in the blood. With the exception of insulin , most GLP-1 receptor agonists ( liraglutide , exenatide , and others), and pramlintide , all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents.

4. Diabetes: Everything You Need to Know, from Symptoms to Treatment

   www.aol.com/diabetes-everything-know-symptoms...

   Diabetes Treatment. Medications are a big part of how diabetes is managed. The type of medication prescribed can depend on the type of diabetes you have. For example, insulin is used to treat type ...

5. Insulin (medication) - Wikipedia

   en.wikipedia.org/wiki/Insulin_(medication)

   There are several challenges involved in the use of insulin as a clinical treatment for diabetes: [38] Mode of administration. Selecting the 'right' dose and timing. The amount of carbohydrates one unit of insulin handles varies widely between persons and over the day but values between 7 and 20 grams per 1 IE is typical.

6. Glucagon receptor agonist - Wikipedia

   en.wikipedia.org/wiki/Glucagon_receptor_agonist

   Combination GLP-1/glucagon receptor agonists provide the thermogenic benefits of glucagon activation while almost eliminating hyperglycemia induced by glucagon receptor activation. Several such drugs have reached human trials for obesity, diabetes, and non-alcoholic fatty liver disease but adverse effects have hampered development. [2]

7. Dipeptidyl peptidase-4 inhibitor - Wikipedia

   en.wikipedia.org/wiki/Dipeptidyl_peptidase-4...

   A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.